vel applications to drive the adoption of the SmartChip platform by researchers around the world who are looking to create improved and more targeted therapeutics," said Dr. Schroth. "Next-generation sequencing has proven to be a powerful discovery platform across basic, applied and clinical research. Since WaferGen's SmartChip System is the most advanced quantitative analysis and validation platform available today, I believe it is going to be widely utilized by researchers seeking to confirm discoveries made with next-generation sequencing. In addition, the high throughput capabilities of the SmartChip system enable researchers to extend their research across large panels of genes, and hundreds of samples, at a very reasonable cost."
Gary P. Schroth, Ph.D., was most recently Senior Director, Research and Development at Illumina, Inc. (and previously Solexa, Inc., which was acquired by Illumina, Inc. in 2007) where he was responsible for expression applications R&D. Prior to Illumina, he held various research and management roles at Applied Biosystems (now part of Life Technologies), Genelabs Technologies, and Gen-Probe. His main research interests are in the areas of gene expression analysis, epigenetics, cancer genomics, and technology development. In his own published research he has used a variety of genomic tools including next-generation DNA sequencing, microarrays, and Real-Time PCR to analyze and study RNA expression and gene regulation. Dr. Schroth is a co-holder of 16 U.S. patents and has co-authored more than 40 peer-reviewed scientific articles on genomic research, including more than 20 papers that use next generation sequencing. He has a BS and Ph.D. in biochemistry from the University of California at Davis.
About WaferGen and the SmartChip Real-Time PCR SystemWaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE WaferGen Biosystems, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. WaferGen Announces Second Quarter 2008 Financial Results2
. WaferGen to Present at the Seventh Annual BIO Investor Forum3
. NIH Awards Approximately $3M Grant for Research Involving WaferGens SmartChip(TM) Real-Time PCR System at the University of Pittsburgh4
. WaferGen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference5
. WaferGen Announces Third Quarter 2008 Financial Results6
. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program7
. Data on WaferGens SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference8
. Data on WaferGens SmartChip(TM) System Presented at 16th International Molecular Medicine Tri-Conference9
. WaferGen to Present Data on SmartChip(TM) Real-Time PCR System at Cambridge Healthtech Institutes Quantitative PCR Conference10
. WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research11
. WaferGen Announces Signing of Private Financing